PIK3CD and neoplasm: Furthermore, our in vitro and in vivo pharmacological study showed significant synergistic effect of PI3K inhibitor copanlisib and MEK inhibitor trametinib to inhibit resistant GC tumor growth when they are combined with lapatinib (Figs. 4 and 5).